News By Tag
News By Location
Neurolixis Appoints Mark H.N. Corrigan, M.D. to Advisory Board
By: Neurolixis, Inc.
Dr. Corrigan is Chairman of the Board of Epirus Biopharmaceuticals, Inc. a public biopharmaceutical company, and from 2010 to 2014, he previously served as a director, president and chief executive officer of Zalicus Inc. prior to its merger with Epirus Biopharmaceuticals in July 2014. Prior to Zalicus, Dr. Corrigan joined the specialty pharmaceutical company Sepracor Inc. in 2003 (now known as Sunovion Pharmaceuticals, Inc.) where he served as Executive Vice President of Research and Development until December 2009. Prior to joining Sepracor, Dr. Corrigan spent 10 years with Pharmacia & Upjohn, where he served most recently as Group Vice President of Global Clinical Research and Experimental Medicine. Before entering pharmaceutical industry, Dr. Corrigan spent five years in academic research at the University of North Carolina, School of Medicine, focusing on psychoneuroendocrinology;
"It is a pleasure to welcome Mark to the Neurolixis Advisory Board," commented Mark Varney, Ph.D., CEO, "Mark brings many years of experience and a deep knowledge of CNS research and development. We look forward to the insights he will provide to facilitate the advancement of our programs at Neurolixis."
About Neurolixis, Inc.
Neurolixis, located in Dana Point, California, is a privately held biotechnology company developing small molecule drugs for the treatment of neurological disorders such as Parkinson’s disease and Rett syndrome and of psychiatric disorders such as depression and schizophrenia. Additional information is available at http://www.neurolixis.com.
Forward Looking Statement Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release.